Clinical Trials Logo

T-Cell Lymphoma Refractory clinical trials

View clinical trials related to T-Cell Lymphoma Refractory.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03046953 Completed - Clinical trials for T-Cell Lymphoma Relapsed

Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma

AVAIL-T
Start date: November 14, 2017
Phase: Phase 2
Study type: Interventional

The AVAIL-T trial is a trial to find out how effective avelumab is at treating patients with primary T-cell lymphoma that is refratory to or has relapsed following initial treatment.